Trial Profile
A Multicenter, Double- Blind, Placebo- Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera (Dimethyl Fumarate) Delayed Release Capsules
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Montelukast (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms MITIGATE
- Sponsors Biogen
- 10 Nov 2017 Status changed from active, no longer recruiting to completed.
- 01 May 2017 Planned End Date changed from 1 Jun 2017 to 15 May 2017.
- 06 Mar 2017 Planned number of patients changed from 295 to 60.